Various healthcare innovations were presented at the American Heart Association's Scientific Sessions 2025, showcasing advancements in cholesterol management for veterans, treatment-resistant depression protocols, cardiovascular health technologies, and the impact of healthy food on heart failure. Additionally, research on cholesterol-lowering medications post-heart transplant and a polypill approach for heart failure patients were highlighted. NanoViricides, Inc. also received regulatory approval for a Phase II clinical trial targeting human pathogenic viruses. Lastly, microscopic wireless electronics for brain surgery could potentially transform treatment procedures for tumors and neurological conditions.